Alcon buys Aerie Pharmaceuticals for $770 million, or 15.25 per share. Aerie Pharmaceuticals develops treatments for patients with glaucoma and other eye diseases. Aerie's two main products are drugs to reduce intraocular pressure and to treat patients with glaucoma or ocular hypertension. Deal is scheduled to close in the fourth quarter of 2022.